Drug intelligence / Profile preview

V7-750

Development stage: Preclinical
Lead developer: University of Louisville
Modality: Peptides
Administration: Intravenous

Overview

V7-750 is a tumor-targeted imaging agent consisting of a pH low insertion peptide (pHLIP) variant, V7, conjugated to the near-infrared fluorescent dye HiLyte 750. It is designed to identify the acidic tumor microenvironment (TME) characteristic of solid tumors like pancreatic adenocarcinoma. The pHLIP technology utilizes the acidic pH of the TME to trigger a conformational change in the peptide, leading to its insertion into the cell membrane and subsequent accumulation of the conjugated imaging probe. V7-750 is being evaluated for use in multispectral optoacoustic imaging (MSOT) and intraoperative fluorescence-guided surgery to improve the detection and resection of pancreatic cancer.

Other names: V7-HiLyte 750V-7-HiLyte 750V 7-HiLyte 750V7-HiLyte Fluor 750V-7-HiLyte Fluor 750V 7-HiLyte Fluor 750

Beyond the preview

Go deeper on V7-750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V7-750.

Explore the full profile